Comparison of baseline and clinical characteristics between age groups showed that the groups were significantly different regarding pathological sub-type, tumor necrosis, invasion status, ER receptor status, HER2 expression status, BC stage, BC grade, grade of nucleus, operation type, site of metastasis, lymph node management, chemotherapy, radiotherapy, hormone therapy, and type of hormone therapy (p < 0.05). This evidence concerns the gene ERBB2 and neoplasm.